See more : Mabuchi Motor Co., Ltd. (6592.T) Income Statement Analysis – Financial Results
Complete financial analysis of Instil Bio, Inc. (TIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Instil Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fabled Copper Corp. (FBCPF) Income Statement Analysis – Financial Results
- Link Holdings Limited (8237.HK) Income Statement Analysis – Financial Results
- Armada Mercantile Ltd. (AAMTF) Income Statement Analysis – Financial Results
- TAJGVK Hotels & Resorts Limited (TAJGVK.BO) Income Statement Analysis – Financial Results
- IGM Financial Inc. (IGM.TO) Income Statement Analysis – Financial Results
Instil Bio, Inc. (TIL)
About Instil Bio, Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 138.00K | 0.00 |
| Cost of Revenue | 4.76M | 5.99M | 2.75M | 0.00 | 20.00K |
| Gross Profit | -4.76M | -5.99M | -2.75M | 138.00K | -20.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 39.60M | 141.06M | 107.25M | 19.40M | 4.03M |
| General & Administrative | 47.55M | 62.24M | 48.31M | 14.38M | 2.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.55M | 62.24M | 48.31M | 14.38M | 2.56M |
| Other Expenses | 72.01M | -564.00K | -1.20M | -4.66M | -5.00K |
| Operating Expenses | 85.79M | 203.29M | 155.56M | 33.78M | 6.59M |
| Cost & Expenses | 90.54M | 203.29M | 155.56M | 33.78M | 6.59M |
| Interest Income | 8.87M | 3.66M | 0.00 | 70.00K | 68.00K |
| Interest Expense | 5.21M | 1.88M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.76M | 5.99M | 2.75M | 256.00K | 20.00K |
| EBITDA | -146.12M | -217.38M | -154.00M | -33.39M | -6.50M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -24,660.14% | 0.00% |
| Operating Income | -159.17M | -226.46M | -155.56M | -33.64M | -6.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -24,379.71% | 0.00% |
| Total Other Income/Expenses | 3.08M | 1.21M | -1.20M | -3.94M | 63.00K |
| Income Before Tax | -156.09M | -225.25M | -156.76M | -37.59M | -6.52M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -27,236.96% | 0.00% |
| Income Tax Expense | 0.00 | -2.07M | 39.00K | 151.00K | -68.00K |
| Net Income | -156.09M | -223.18M | -156.79M | -37.74M | -6.45M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -27,346.38% | 0.00% |
| EPS | -24.00 | -34.46 | -24.30 | -5.89 | -1.01 |
| EPS Diluted | -24.00 | -34.46 | -24.30 | -5.89 | -1.01 |
| Weighted Avg Shares Out | 6.50M | 6.48M | 6.45M | 6.41M | 6.41M |
| Weighted Avg Shares Out (Dil) | 6.50M | 6.48M | 6.45M | 6.41M | 6.41M |
Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright
Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of Precision BioSciences in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now...
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update.
What Makes Instil Bio (TIL) a New Buy Stock
Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate...
Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why
Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.
Instil Bio Announces Strategic Update
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced a strategic...
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that a...
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its third quarter 2023 financial...
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple...
After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)
The heavy selling pressure might have exhausted for Instil Bio, Inc. (TIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the...
Source: https://incomestatements.info
Category: Stock Reports